Preclinical data further support the potential of dual-antigen and TGF-β-directed vaccines to reshape the tumor microenvironment and drive anti-tumor immunity NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) ...

Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to ...

Radiant Biotherapeutics Announces Poster Presentation at 2025 American Association for Cancer Research (AACR) Annual Meeting ...

Presentations at this year’s American Association for Cancer Research meeting could have a broad impact on the treatment ...

The US Food and Drug Administration on Wednesday approved a cancer drug developed by China-based Akeso Inc, marking a ...

Merck’s first-quarter net income increased as sales of its Keytruda cancer drug rose, but the Big Pharma company cut its 2025 ...